Scynexis Initiates Phase 1 Study of SCY-770 to Treat Autosomal Dominant Polycystic Kidney Disease

MT Newswires Live

06/30

Scynexis (SCYX) said Tuesday that it has initiated a phase 1 study of SCY-770 to treat autosomal dominant polycystic kidney disease.

Autosomal dominant polycystic kidney disease can cause pain, high blood pressure and kidney failure in patients.

The biotech company said the study will characterize the food-effect and define the pharmacokinetics of two dosing regimens for SCY-770 to support dose selection for the phase 2 study, which it said is on track for Q4.

Topline data for the phase 1 study is expected to be released in Q3, according to Scynexis.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2647515485"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2647515485\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2647515485?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 21:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647515485","market":"sg","top_or_hot":-1,"title":"Scynexis Initiates Phase 1 Study of SCY-770 to Treat Autosomal Dominant Polycystic Kidney Disease","media":"MT Newswires Live","content":"<html><body><p> Scynexis (SCYX) said Tuesday that it has initiated a phase 1 study of SCY-770 to treat autosomal dominant polycystic kidney disease.</p><p>Autosomal dominant polycystic kidney disease can cause pain, high blood pressure and kidney failure in patients.</p><p>The biotech company said the study will characterize the food-effect and define the pharmacokinetics of two dosing regimens for SCY-770 to support dose selection for the phase 2 study, which it said is on track for Q4.</p><p>Topline data for the phase 1 study is expected to be released in Q3, according to Scynexis.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Scynexis Initiates Phase 1 Study of SCY-770 to Treat Autosomal Dominant Polycystic Kidney Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nScynexis Initiates Phase 1 Study of SCY-770 to Treat Autosomal Dominant Polycystic Kidney Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-30 21:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Scynexis (SCYX) said Tuesday that it has initiated a phase 1 study of SCY-770 to treat autosomal dominant polycystic kidney disease.</p><p>Autosomal dominant polycystic kidney disease can cause pain, high blood pressure and kidney failure in patients.</p><p>The biotech company said the study will characterize the food-effect and define the pharmacokinetics of two dosing regimens for SCY-770 to support dose selection for the phase 2 study, which it said is on track for Q4.</p><p>Topline data for the phase 1 study is expected to be released in Q3, according to Scynexis.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SCYX","symbol_name":"SCYNEXIS Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2647515485","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647515485","pubTimestamp":1782826132,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Scynexis  said Tuesday that it has initiated a phase 1 study of SCY-770 to treat autosomal dominant polycystic kidney disease.Autosomal dominant polycystic kidney disease can cause pain, high blood pressure and kidney failure in patients.The biotech company said the study will characterize the food-effect and define the pharmacokinetics of two dosing regimens for SCY-770 to support dose selection for the phase 2 study, which it said is on track for Q4.Topline data for the phase 1 study is expected to be released in Q3, according to Scynexis.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SCYX":"SCYNEXIS Inc","BK4007":"制药","SCY":"Simplify US Small Cap PLUS Income ETF"},"translate_title":"Scynexis启动SCY-770治疗常染色体显性多囊肾病的1期研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SCYX":1,"SCY":1.5},"content_text":"Scynexis (SCYX) said Tuesday that it has initiated a phase 1 study of SCY-770 to treat autosomal dominant polycystic kidney disease.Autosomal dominant polycystic kidney disease can cause pain, high blood pressure and kidney failure in patients.The biotech company said the study will characterize the food-effect and define the pharmacokinetics of two dosing regimens for SCY-770 to support dose selection for the phase 2 study, which it said is on track for Q4.Topline data for the phase 1 study is expected to be released in Q3, according to Scynexis.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}